Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Krystal Biotech Community
NasdaqGS:KRYS Community
1
Narratives
written by author
0
Comments
on narratives written by author
15
Fair Values set
on narratives written by author
Create a narrative
Krystal Biotech
Popular
Undervalued
Overvalued
Community Investing Ideas
Krystal Biotech
AN
AnalystConsensusTarget
Consensus Narrative from 10 Analysts
Anticipated VYJUVEK Launch In EU And Japan Will Expand International Reach
Key Takeaways Anticipated international market expansion and product diversification could boost revenue through successful launches and positive clinical progress. Scaling up manufacturing processes and diversifying pipeline offerings aim to enhance operational efficiency and support long-term growth.
View narrative
US$214.80
FV
23.2% undervalued
intrinsic discount
41.57%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
4 days ago
author updated this narrative
Your Valuation for
KRYS
KRYS
Krystal Biotech
Your Fair Value
US$
Current Price
US$165.00
54.8% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-140m
914m
2015
2018
2021
2024
2025
2027
2030
Revenue US$913.6m
Earnings US$280.4m
Advanced
Set Fair Value